Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib

Biochemical and Biophysical Research Communications

Volumn 342, Issue 3, 2006, Pages 940-948

  Niederberger, Ellen ^a   Manderscheid, Christine ^a   Geisslinger, Gerd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

COX 2; Etoricoxib; Lumiracoxib; Macrophages; NSAIDs; Transcription factor

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LUMIRACOXIB; PROSTAGLANDIN SYNTHASE; PROTEIN C FOS; PROTEIN C JUN; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL NUCLEUS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DINOPROSTONE; GENE EXPRESSION REGULATION; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; ORGANIC CHEMICALS; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; PYRIDINES; SULFONES; TRANSCRIPTION FACTOR AP-1;

ANIMALIA;

EID: 33644617181     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.02.040     Document Type: Article

References (31)

1. B.S. Reddy, C.V. Rao, and K. Seibert Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis Cancer Res. 56 1996 4566 4569
2. C.V. Rao, A. Rivenson, B. Simi, E. Zang, G. Kelloff, V. Steele, and B.S. Reddy Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent Cancer Res. 55 1995 1464 1472
3. D.L. Simmons, R.M. Botting, and T. Hla Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol. Rev. 56 2004 387 437
4. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M.B. Ferraz, C.J. Hawkey, M.C. Hochberg, T.K. Kvien, and T.J. Schnitzer Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group N. Engl. J. Med. 343 2000 1520 1528 1522 p following 1528
5. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, M.A. Konstam, and J.A. Baron Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N. Engl. J. Med. 352 2005 1092 1102
6. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, and M. Bertagnolli Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N. Engl. J. Med. 352 2005 1071 1080
7. N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, S.W. Boyce, and K.M. Verburg Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N. Engl. J. Med. 352 2005 1081 1091
8. B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, and G.A. FitzGerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc. Natl. Acad. Sci. USA 96 1999 272 277
9. S. Van Doornum, G. McColl, and I.P. Wicks Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46 2002 862 873
10. O. Belton, D. Byrne, D. Kearney, A. Leahy, and D.J. Fitzgerald Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis Circulation 102 2000 840 845
11. G.A. Fitzgerald Coxibs and cardiovascular disease N. Engl. J. Med. 351 2004 1709 1711
12. S.P. Johnsen, H. Larsson, R.E. Tarone, J.K. McLaughlin, B. Norgard, S. Friis, and H.T. Sorensen Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study Arch. Intern. Med. 165 2005 978 984
13. J.M. Dogne, C.T. Supuran, and D. Pratico Adverse cardiovascular effects of the coxibs J. Med. Chem. 48 2005 2251 2257
14. S.D. Martina, K.S. Vesta, and T.L. Ripley Etoricoxib: a highly selective COX-2 inhibitor Ann. Pharmacother. 39 2005 854 862
15. B. Bannwarth, and F. Berenbaum Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor Expert Opin. Invest. Drugs 14 2005 521 533
16. M.E. Farkouh, H. Kirshner, R.A. Harrington, S. Ruland, F.W. Verheugt, T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, E. Ehrsam, X. Gitton, G. Krammer, B. Mellein, A. Gimona, P. Matchaba, C.J. Hawkey, and J.H. Chesebro Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial Lancet 364 2004 675 684
17. R. Esser, C. Berry, Z. Du, J. Dawson, A. Fox, R.A. Fujimoto, W. Haston, E.F. Kimble, J. Koehler, J. Peppard, E. Quadros, J. Quintavalla, K. Toscano, L. Urban, J. van Duzer, X. Zhang, S. Zhou, and P.J. Marshall Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2 Br. J. Pharmacol. 144 2005 538 550
18. A.N. McEvoy, B. Bresnihan, O. FitzGerald, and E.P. Murphy Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue Arthritis Rheum. 50 2004 1132 1145
19. J. Morel, and F. Berenbaum Signal transduction pathways: new targets for treating rheumatoid arthritis Joint Bone Spine 71 2004 503 510
20. J.E. Reusch, and D.J. Klemm Cyclic AMP response element-binding protein in the vessel wall: good or bad? Circulation 108 2003 1164 1166
21. F. Chen, P. Eriksson, G.K. Hansson, I. Herzfeld, M. Klein, L.O. Hansson, and G. Valen Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque Int. J. Mol. Med. 15 2005 57 65
22. C. Monaco, and E. Paleolog Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis Cardiovasc. Res. 61 2004 671 682
23. L.C. Green, D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannenbaum Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids Anal. Biochem. 126 1982 131 138
24. H.L. Pahl Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 18 1999 6853 6866
25. P.A. Baeuerle Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr. Biol. 8 1998 R19 R22
26. B. Mayr, and M. Montminy Transcriptional regulation by the phosphorylation-dependent factor CREB Nat. Rev. Mol. Cell Biol. 2 2001 599 609
27. S. Grosch, I. Tegeder, K. Schilling, T.J. Maier, E. Niederberger, and G. Geisslinger Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers FASEB J. 20 2003
28. I. Tegeder, J. Pfeilschifter, and G. Geisslinger Cyclooxygenase- independent actions of cyclooxygenase inhibitors FASEB J. 15 2001 2057 2072
29. T.J. Maier, A. Janssen, R. Schmidt, G. Geisslinger, and S. Grosch Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells FASEB J. 19 2005 1353 1355
30. E. Niederberger, I. Tegeder, G. Vetter, A. Schmidtko, H. Schmidt, C. Euchenhofer, L. Brautigam, S. Grosch, and G. Geisslinger Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB FASEB J. 15 2001 1622 1624
31. E. Niederberger, I. Tegeder, C. Schafer, M. Seegel, S. Grosch, and G. Geisslinger Opposite Effects of Rofecoxib on Nuclear Factor-kappaB and Activating Protein-1 Activation J. Pharmacol. Exp. Ther. 304 2003 1153 1160